Labcorp announces clinical availability of liquid biopsy test to guide personalized treatment plans for patients with advanced solid tumors

Labcorp® plasma completetm offers oncologists a highly sensitive and specific genomic profiling solution from a simple blood draw burlington, n.c. , feb. 24, 2025 /prnewswire/ -- labcorp (nyse: lh), a global leader of innovative and comprehensive laboratory services, announced today the clinical availability of labcorp® plasma completetm , a circulating tumor dna (ctdna)-based comprehensive genomic profiling solution for patients with advanced solid tumors.
LH Ratings Summary
LH Quant Ranking